Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Alecensa

- PMLiVE

AstraZeneca unveils plans to deliver $80bn in total revenue by 2030

The company expects to launch 20 new medicines by the end of the decade

- PMLiVE

Study reveals new breast cancer genes found in women of African ancestry

More than 240,000 cases of breast cancer are diagnosed in the US every year

- PMLiVE

Roche announces FDA approval of self-collection solution for HPV screening

More than 13,000 people are diagnosed with cervical cancer every year in the US

- PMLiVE

ICR researchers reveal key driver of PARP inhibitor resistance in advanced breast cancer

Currently the most common cancer in the UK, breast cancer affects over 55,000 people annually

- PMLiVE

Johnson & Johnson shares positive results for TAR-200 in high-risk bladder cancer

More than 83,000 cases of bladder cancer are diagnosed in the US every year

- PMLiVE

Navigating the rapidly changing oncology treatment landscape: how digital tools can help

With rapid growth comes growing pains...

Impetus Digital

- PMLiVE

Showing Deep Expertise at ONS

The Medscape Oncology team will be connecting with the oncology nursing community this week in Washington, DC for the ONS Congress 2024.  Medscape Oncology has deep expertise in the oncology...

Medscape Education Global

- PMLiVE

Infographic: Therapy Watch Acute Myeloid Leukemia market snapshot

This Acute Myeloid Leukemia infographic offers a snapshot of the real-world patient insights collected by our Therapy Watch study, based on data collected from a panel of 220 physicians across...

Research Partnership

- PMLiVE

Roche’s ALK inhibitor Alecensa receives FDA approval to treat early-stage NSCLC

Approximately half of all patients with early lung cancer experience cancer recurrence following surgery

- PMLiVE

Roche reveals promising phase 3 results for subcutaneous Ocrevus in progressive and relapsing MS

The chronic neurological condition affects more than 2.8 million people worldwide

- PMLiVE

UK scientists reveal promising new treatment strategy for acute myeloid leukaemia

The aggressive form of blood cancer is responsible for more than 3,000 new cases in the UK every year

- PMLiVE

Roche receives FDA breakthrough device designation for Alzheimer’s disease blood test

Around 55 million people globally are living with dementia, which is estimated to rise to 139 million by 2050

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links